skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

8 Total results for product and free and sample content found

Scrip

NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations

By Joseph Haas 13 Feb 2017

New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum.

Topic immuno-oncology

Scrip

Pressure On Tecentriq: Bladder Cancer Heats Up

By Emily Hayes 03 Feb 2017

Merck's filings in bladder cancer span first-line and second-line treatment and include overall survival data. Roche also is getting ready to move Tecentriq to the frontline setting.

Topic Clinical trials immuno-oncology

Scrip

Therapeutic Progress Amid Political Turbulence: Could 2017 Be Pharma's Year?

By Eleanor Malone 12 Dec 2016

Delivering clinical advances in areas including immuno-oncology and Alzheimer's disease data while navigating the stormy seas of global politics could represent an opportunity for pharma to influence change. An uptick in sector M&A could also ensue if Trump offers US corporations a tax holiday.

Topic immuno-oncology

Datamonitor Healthcare

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 26 Oct 2016

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Topic immuno-oncology

Scrip

Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology

By Jessica Merril 10 Oct 2016

Merck’s strong Phase II data testing Keytruda with chemotherapy

Topic immuno-oncology

Biomedtracker

​Analyzing ASCO 2016

13 Jun 2016

Topic immuno-oncology

Datamonitor Healthcare

Need help entering the Ulcerative Colitis market?

14 Sep 2015

Entering an established market as a new player can be daunting. Often it's difficult to know exactly where you should be targeting your trial, and also what patient group you should be targeting your treatment at.

Topic immuno-oncology

Pharmaprojects

Anticancer Immunotherapy - A New Weapon Against Cancer

By Jonathan Stephens 06 Jul 2015

Since its inception in the mid-20th century, chemotherapy has been the mainstay of cancer treatment and has become increasingly specific and effective. 

Topic immuno-oncology

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: